A Flawed Study Shows How Little We Understand Crispr's Effects
By Megan Molteni,
Wired
| 04. 02. 2018
BIOTECH HAS BEEN betting big on Crispr, the gene-editing technique that promises to snip away some of humanity’s worst diseases. But last May, a small case study suggested the much-hyped technology might actually be quite dangerous—and pop went the Crispr bubble, briefly tanking shares of Crispr companies like Editas Medicine, Intellia Therapeutics, and Crispr Therapeutics.
It was an overreaction, as so many market spikes and dips turn out to be; the company CEOs were quick to push back, and scientists and journalists soon pointed out flaws in the paper that misconstrued cause and effect. After nearly a year of continued criticisms, and failures to reproduce the results, the authors conceded that the skeptics might be right. Last week, the journal that published the paper, Nature Methods, finally retracted it.
But that doesn’t mean that Crispr has been given the all-clear. The now-retracted paper claimed that Crispr caused nearly 2,000 unexpected mutations—ten times previously observed off-target rates—in two mice that it cured of blindness. But just as that evidence should never have been enough to squash Crispr’s clinical potential, neither...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...